Loading data for BOLD — first visit, this takes a few seconds.
Boundless Bio Inc. (BOLD)
NasdaqGS: BOLD
· Precio en tiempo real · USD
2.83
+0.00 (0.00%)
Al cierre: Aug 17, 2026, 8:00 PM
Boundless Bio Inc. (BOLD) Stock Price, Analysis & Data
0.00% (1D)
No hay datos disponibles
| Precio de compra | 2.05 |
| Capitalización de mercado | 64.38M |
| Ingresos (TTM) | n/a |
| Beneficio neto (TTM) | -64.01M |
| Beta | 0.38 |
| EPS (TTM) | -2.85 |
| Ratio PER (TTM) | n/a |
| Adelante PE | -2.89 |
| P/B (TTM) | 0.96 |
| P/S (TTM) | n/a |
| Earnings Date | n/a |
| Precio de venta | 2.84 |
| Volumen | 139,046 |
| Volumen medio (20D) | 1,288,870 |
| Abierto | 2.77 |
| Anterior Cerrar | 2.83 |
| Rango del día | 2.71 - 2.88 |
| Rango de 52 semanas | 0.96 - 2.97 |
| analista | n/a |
| Precio objetivo | n/a |
| Dividendos | n/a |
| Fecha ex dividendo | n/a |
Acerca de BOLD
Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-...
Industria Biotechnology
Sector Healthcare
IPO Fecha Mar 28, 2024
Empleados 28
Bolsa de Valores NasdaqGS
Símbolo bursátil BOLD
Sitio web https://boundlessbio.com
Desempeño financiero
En 2025, los ingresos de Boundless Bio fueron 0, un aumento de undefined% en comparación con 0 del año anterior. Las ganancias fueron -58.2M, una disminución de -10.96%.
Estados financierosSorpresa de resultados
Boundless Bio ha publicado sus resultados trimestrales en Aug 7, 2026:
Página 1 de 2